Delivery Order W911SR22D0009-W911SR22F0014
Award Date
1/4/22
Potential Completion Date
2/29/28
Potential Value
$108M
Funding Federal Agency
Joint PEO Chemical and Biological Defense
Contracting Federal Agency
ACC Aberdeen Proving Ground
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Available for Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Fort Detrick, MD 21702, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Walsh Healy Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $6,821,012.21 Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for the development of a broad spectrum monoclonal antibody-based therapeutic for botulism, a biological threat. The contract has no set-aside designation and the ultimate completion date is September...
This federal contract award to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) is valued at $9,080,310.52 and was issued by the Joint PEO Chemical and Biological Defense, part of the U.S. Department of the Army. The award is for drug substance process validation, drug product process validation, clinical development phase 3, and storage/stability activities to support the U.S. FDA licensure of the BONT MAB G03-52-01 drug product. The contract was awarded on March...
This is a definitive contract awarded by the Department of the Army's Joint PEO Chemical and Biological Defense, a defense agency, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $366,290,602.35 cost-plus-fixed-fee contract is for the Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) Capability, with a period of performance through October 31, 2023. As a prime contractor, Resilience has provided a range of goods and services related...
This federal contract award, W911SR22D0009|W911SR22F0073, was issued by the Joint Program Executive Office for Chemical and Biological Defense, a Defense agency, to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The $4,861,155.86 contract is a Delivery Order under a Cost Plus Fixed Fee contract type, with a period of performance ending on February 28, 2025. The contract supports DS Process Characterization, which likely refers to characterization and development of...
This is a $190,241,861.21 Other Transaction Agreement awarded by the Department of the Army's Joint PEO Chemical and Biological Defense to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.), a technology-focused biomanufacturing company. The contract does not have a set-aside designation. The agreement, awarded on February 21, 2020, supports the development and manufacturing of medical countermeasures against biological threats and COVID-19. Resilience has provided...
This federal contract award, W911QY2190008, was issued by the Joint PEO Chemical and Biological Defense, a subcomponent of the U.S. Department of the Army, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $62,096,250.00 Other Transaction Agreement is for the development of a "COVID-19" Monoclonal Antibody (MAB) Sponsorship Prototype. Resilience Government Services, a technology-focused biomanufacturing company, has previously received federal...
This is a $799,780 cost-plus-fixed-fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for the development of analytical methods, upstream and downstream manufacturing processes, scale-up production, and release testing for the LNA14 product. This delivery order falls under a larger...
This is a $3,044,549.00 fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for biomedical research and development work, with a period of performance ending on March 31, 2010. No set-aside designations were used. Resilience Government Services, a technology-focused biomanufacturing company, has...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $5,107,357.36 Other Transaction Agreement to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., a technology-focused biomanufacturing company. The contract, which has no set-aside designation, is for the development of a "Plasmid Platform Protype" and is part of a larger $5.7 million Indefinite Delivery Vehicle aimed at transferring capabilities to...
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The $29,026,970.00 cost-plus-fixed-fee contract was awarded on September 9, 2019 to perform work under HHS-NIH-NIAID-BAA2018. The contract has an ultimate completion date of August 17, 2024 and does not have a set-aside designation....